MASCT-1

MASCT-1 (Multiple Antigen Stimulating Cellular Therapy-I) is a novel immunotherapy designed for the treatment of advanced solid tumors and various cancers. It is a sequential immune cell therapy that involves generating dendritic cells (DCs) from autologous peripheral blood. These DCs are loaded with multiple tumor antigens and re-infused into the patient to stimulate autologous T-cell proliferation and induce specific cytotoxic T-cells (CTLs). The process typically includes several subcutaneous DC injections followed by adoptive transfer of anti-tumor effector T-cells. In some protocols, MASCT-1 is combined with immune checkpoint inhibitors such as camrelizumab (a PD-1 antibody), or tyrosine kinase inhibitors like apatinib. The addition of PD-1 blockade can occur both in vivo and during in vitro culture to enhance the anti-tumor activity by relieving inhibitory signals on immune cells[2][3][4][6]. Clinical studies have shown that MASCT-1 alone or in combination regimens is generally well tolerated with manageable adverse events such as mild rash, fever, muscle cramps, and arthralgia; serious adverse events are rare[5]. Early-phase trials indicate promising efficacy signals across metastatic urothelial carcinoma, soft tissue sarcoma, non-small cell lung cancer, liver cancer, gastric cancer and other advanced solid tumors[2][3][5].

Other names

Cytotoxic T-cell therapy - HengRui YuanZhengDendritic cell therapy - HengRui YuanZheng